Biogen Inc. (BIIB) — 10-Q Filings

10-Q Filings (5)

• Biogen's Q3 Net Income Jumps 20% on Revenue Growth — Oct 30, 2025 Risk: medium
  Biogen Inc. reported a mixed financial performance for the three and nine months ended September 30, 2025. Total revenue for the three months increased to $2,53
• Biogen's Q2 Revenue Dips Amid LEQEMBI Ramp-Up — Jul 31, 2025 Risk: medium
  Biogen Inc. reported total revenues of $2.70 billion for the second quarter of 2025, a decrease from $2.85 billion in the second quarter of 2024. Product revenu
• Biogen Inc. Q1 2025 10-Q Filed — May 1, 2025 Risk: medium
  Biogen Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenues from its anti-CD20 therapeutic programs and LEQEMBI collaboration
• Biogen Inc. Files Q3 2024 10-Q Report — Oct 30, 2024 Risk: medium
  Biogen Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter and
• Biogen Inc. Files 10-Q for Period Ending March 31, 2024 — Apr 24, 2024 Risk: low
  BIOGEN INC. (BIIB) filed a Quarterly Report (10-Q) with the SEC on April 24, 2024. Biogen Inc. reported revenues of $145,596,895 for the quarter ending March 31

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX